SecBot SecBot
144 ·Filed May 11, 2026

RAPP

Rapport Therapeutics, Inc.
BEARISH
Impact 5/10
Horizondays Processed5mo ago SEC0001974078-26-000178
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

A major pre-IPO venture backer is systematically reducing its stake, with over $24M in proposed and completed sales in the past month. This is a strong negative signal for near-term price support. Monitor for additional Form 144 filings and any lock-up expiration events.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
RAPP ▲ +24.46% at T+60d
SHORT call ✗ call lost -24.46% · α vs SPY -20.08% · entry $37.24 → $46.35
Entry anchored
May 11, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.54%
$37.24
settled 6mo ago
T+5d
-5.53%
call +5.53% · α +5.61%
$35.18
settled 5mo ago
T+20d
-5.45%
call +5.45% · α +3.72%
$35.21
settled 5mo ago
T+60d
+24.46%
call -24.46% · α -20.08%
$46.35
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 to sell 133,618 shares of Rapport Therapeutics common stock, valued at approximately $5.38 million. This follows recent insider sales totaling $18.7M over the past 30 days, signaling continued insider monetization.

Key Facts

  • Third Rock Ventures V, L.P. (10% stockholder) intends to sell 133,618 shares of RAPP common stock.
  • Estimated aggregate sale value: $5,378,124.50.
  • Proposed sale date: May 11, 2026.
  • Recent insider activity (30d): 4 sells totaling $18.7M.
  • Third Rock has sold 702,518 shares in three separate transactions in the past month (April 17, May 7, May 8).

Financial Impact

Proposed sale of $5.38M by a major venture backer, adding to $18.7M in recent insider sales.

dilutioninsider selling pressure

Risk Factors

  • Continued insider selling by major shareholders could pressure the stock.
  • Venture backer liquidation may signal lack of confidence in near-term catalysts or valuation.
  • Potential for additional unregistered sales as Third Rock reduces its position.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974078-26-000178
Document: 0001974078-26-000178-index.html0001974078-26-000178
Document: 0001974078-26-000178.txt0001974078-26-000178
22 reports for RAPP
Performance horizon
60% Hit rate @ T+5 3 of 5 directional calls Went positive at some point 5 of 7 best @ T+60▲ +24.87%Mar 10, 2026
Filters
Rows
Reports for RAPP — sortable, filterable
TypeNow
Oct 23, 2026
2d ago
Insider Cluster
BULLISH ★ 5/10
$26.00awaiting T+5—$25.93 (−0.27%)
Oct 22, 2026
4d ago
Insider Cluster
BULLISH ★ 5/10
$27.33awaiting T+5—$25.93 (−5.12%)
Oct 21, 2026
4d ago
Insider Buy
BULLISH ★ 4/10
$26.53awaiting T+5—$25.93 (−2.26%)
Oct 20, 2026
6d ago
8-K
BULLISH ★ 7/10
$29.37awaiting T+5—$25.93 (−11.71%)
Oct 6, 2026
19d ago
144
BEARISH ★ 5/10
$30.86 $28.33▲ +8.20%▲ +7.22%$25.93 (+15.98%)
Oct 1, 2026
24d ago
Insider Cluster
NEUTRAL ★ 3/10
$32.17 $30.65▼ −4.72%▼ −5.89%$25.93 (−19.40%)
Aug 26, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.83 $47.65▼ −6.26%▼ −6.52%$25.93 (−48.99%)
Aug 5, 2026
11w ago
8-K
MIXED ★ 5/10
$42.44 $47.73▲ +12.46%▲ +12.11%$25.93 (−38.90%)
Jul 1, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$38.97 $41.75▲ +7.13%▲ +5.77%$25.93 (−33.46%)
Jun 30, 2026
16w ago
144
NEUTRAL ★ 2/10
$39.39 $39.72▲ +0.84%▲ +0.58%$25.93 (−34.17%)
Showing 10 of 22

US Market Status

Market Closed — Opens in 2h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers